SAN DIEGO, Aug. 24, 2015 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, promoted
Sheela Mohan-Peterson, JD, MS, to
Chief Legal and Compliance Officer, effective August 24, 2015. In this role, Ms. Mohan-Peterson
will advise the Company's officers and Board of Directors on all
major legal matters and continue to lead the Company's intellectual
property portfolio and global legal strategy.
"Sheela has provided valuable leadership and counsel, which has
contributed to the growth and success of OncoSec over the past
year," said Punit Dhillon, President
and CEO of OncoSec. "Her extensive legal expertise has allowed us
to expand our intellectual property portfolio by leveraging our
R&D and preclinical activities. I expect Sheela will continue
to balance risks and opportunities as we navigate new business
growth opportunities in this expanded role."
Ms. Mohan-Peterson has spent 29 years working in the
pharmaceutical and biotech industries and joined OncoSec in
September 2014, serving as General
Counsel and Corporate Secretary. She was most recently a Senior
Patent Counsel at Merck & Co., Inc. Ms. Mohan-Peterson also
held patent counsel positions at several companies including:
Schering-Plough Biopharma, DNAX Research Institute, Incyte
Genomics, and Roche Bioscience. She received her bachelor's degree
in Biology from Washington University
in St. Louis, her master's degree
in Biology from Rutgers University, and
her law degree from Peninsula (now Lincoln)
University (CA).
About OncoSec Medical Incorporated
OncoSec is a
biopharmaceutical company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse™,
for the treatment of cancer. ImmunoPulse™ is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various skin
cancers as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently
in Phase II development for several indications, including
metastatic melanoma, squamous cell carcinoma of the head and neck
(HNSCC), and triple-negative breast cancer (TNBC). In addition to
ImmunoPulse™ IL-12, the company is also identifying and developing
new immune-targeting agents for use with the ImmunoPulse™ platform.
For more information, please visit www.oncosec.com.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-promotes-sheela-mohan-peterson-to-chief-legal-and-compliance-officer-300131647.html
SOURCE OncoSec Medical Incorporated